New SARS-CoV-2 variants have rendered ineffective most US Food and Drug Administration-approved COVID-19 antibody treatments and reduced vaccine efficacy.
Support the development of new human monoclonal antibodies with potent activity against Omicron strains with licensing or direct investment.
The innovation
Human monoclonal antibodies with high binding affinity as well as the potent and broad neutralisation against SARS-CoV-2 variants Alpha, Beta, Gamma, Kappa, Delta and Omicron.
Market need
The Omicron variant is highly resistant against antibody-mediated neutralisation. Most monoclonal antibodies that were previously used to treat severe COVID-19 have lost efficacy against the Omicron variant.
Innovation status
The University of Melbourne human monoclonal antibodies are highly effective against SARS-CoV-2 variants in vitro and in animal models. The research team is working on generating a stable cell line for manufacturing a monoclonal antibody product suitable for Phase 1 clinical trial.
Contact
Anna Malinovitch
anna.malinovitch@unimelb.edu.au
Flyer
Download flyer for more information (PDF)
Keep reading
-
Negotiating a licence with the University
By licensing the University of Melbourne’s intellectual property (IP) and technologies, you can harness research discoveries to solve business challenges.
-
Our IP principles
Our Intellectual Property (IP) management principles make it easier to collaborate with us.
-
Investing in University startups
Find out about new ways to invest in University startups
-
Contact
From developing an idea to finding startup funding, the University of Melbourne’s team of experts can help.